I lead Memorial Sloan Kettering’s efforts in animal imaging with MRI. Our facility performs high-resolution, large-volume in vivo cancer screening in rodents and other animals, as well as other experimental MRI services.
My research interests include the development and application of new MRI, multi-nuclear spectroscopic imaging, and multi-modal imaging methods to aid in cancer diagnosis and treatment monitoring, and in studying tumor hypoxia (oxygen deprivation), angiogenesis (the formation of new blood vessels that promote tumor growth), and tumor metabolism.
Dynamic contrast-enhanced MRI is well-suited for measuring in vivo tumor perfusion, which reveals abnormalities in the vasculature of a tumor. Understanding tumor perfusion can also help in interpreting other trace-based imaging methods, such as PET. New measurement and compartmental modeling methods are being developed for various imaging applications. We are also developing new multi-modal imaging methods to detect tumor hypoxia, such as co-registered MRI and PET.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Carl C. Lekaye discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.